Zac Germon

64 posts

Zac Germon

Zac Germon

@ZacGermon

Post Doctoral Scientist @ University of Newcastle | Cell Signalling | Proteomics | Leukaemia + DIPG | CSRG #DunLab

شامل ہوئے Eylül 2019
158 فالونگ110 فالوورز
Zac Germon ری ٹویٹ کیا
Hawkins Lab
Hawkins Lab@CHawkinsLab·
proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases academic.oup.com/neuro-oncology…
English
0
4
20
2K
Charles de Bock
Charles de Bock@charles_debock·
Following our publication on T-ALL this week, pleased to share another paper from our group now published in @NatureComms linking PU.1 to glucocorticoid sensitivity in B-ALL rdcu.be/dZB01 which was a massive team effort @KidsCancerInst ; 🧵n/8 below
English
6
5
32
2.7K
Zac Germon
Zac Germon@ZacGermon·
Had a great day at @TheASMR1 Hunter meeting. Grateful to have been awarded Best ECR/MCR talk on the day!
Zac Germon tweet media
English
2
1
7
237
Zac Germon
Zac Germon@ZacGermon·
Thanks @CancerAustralia & @KidsCancerProj! Excited to be given the opportunity to continue this project investigating much needed novel treatment strategies for Paediatric cancers #AML #DMG #DIPG
Matt Dun, PhD@MattDun17

Delighted #DunLab 's childhood cancer project was funded by @CancerAustralia & @KidsCancerProj Free-radicals (#ROS) promote cancer signaling in RTK mutant- #AML & #DMG #DIPG Here we will develop new targeted treatments Congrats @ZacGermon @duchatel_ryan @Jonatha16752881 DE & ID

English
0
2
9
676
Zac Germon ری ٹویٹ کیا
Matt Dun, PhD
Matt Dun, PhD@MattDun17·
Wonderful to see the glossy version & cover of #DunLab’s latest paper discovering the genetic dependency & targeting of PI3K in #DIPG #DMG Huge thanks to the funders & parents who donated their child’s tissues to help us in this & all our important studies doi.org/10.1172/JCI170…
Journal of Clinical Investigation@jclinicalinvest

#Cover: Targeting PI3K/mTOR in diffuse intrinsic pontine glioma: buff.ly/3TAz4Jd #Image presents a model whereby the connectivity of these cancers can be harnessed using integrated technologies to identify potential therapeutic strategies. #Oncology #Therapeutics

English
1
14
74
6.1K
Dr William Reay
Dr William Reay@williamreay96·
Happy to announce that 2024 marks a new chapter for me as I'm joining the Menzies Institute for Medical Research in the beautiful city of Hobart, a place very close to my heart. I'm very excited for this opportunity and look forward to further developing my research program here.
English
8
1
56
2.7K
Zac Germon ری ٹویٹ کیا
Matt Dun, PhD
Matt Dun, PhD@MattDun17·
What a team #DunLab 2023-2024
Matt Dun, PhD tweet media
English
2
3
60
2.3K
Matt Dun, PhD
Matt Dun, PhD@MattDun17·
What’s better than watching & being part of your PhD students- Dr @ZacGermon, now superstar postdoc’s, graduation.. Not much! Congratulations mate, thanks for choosing me as your supervisor & for your handwork, dedication & friendship #DunLab #CSRG @PrecisionMedUON @UON_research
Matt Dun, PhD tweet media
English
1
2
50
1.5K
Zac Germon ری ٹویٹ کیا
Science Signaling
Science Signaling@scisignal·
A new study shows that inhibiting the oxidase NOX2 suppresses a common subtype of #AcuteMyeloidLeukemia (AML) in mice by blocking ROS in cancer cells—hinting that targeting NOX2 may potentiate precision therapies for AML. @ZacGermon @MattDun17 scim.ag/26a
Science Signaling tweet media
English
0
5
15
2.4K
Zac Germon ری ٹویٹ کیا
Matt Dun, PhD
Matt Dun, PhD@MattDun17·
Probably my favourite part of adding to the literature, students/stuff pinning their first author papers to our walls of honour! #DunLab #CSRG
Matt Dun, PhD tweet media
Matt Dun, PhD@MattDun17

#DunLab paper alert: Patients diagnosed with the most common driver mutation in acute myeloid leukemia (AML) – FLT3, are associated with poor-outcomes. FLT3+ AML sees the overproduction of reactive oxygen species (ROS), a second messenger signaling (T1) doi.org/10.1126/scisig…

English
4
4
64
9.8K
Zac Germon
Zac Germon@ZacGermon·
Excited to see this paper published today in @scisignal. This work formed a large part of my PhD and is summarised below:
Matt Dun, PhD@MattDun17

#DunLab paper alert: Patients diagnosed with the most common driver mutation in acute myeloid leukemia (AML) – FLT3, are associated with poor-outcomes. FLT3+ AML sees the overproduction of reactive oxygen species (ROS), a second messenger signaling (T1) doi.org/10.1126/scisig…

English
4
4
18
2.2K